Novo Nordisk Aktie News

Novo Nordisk's (NYSE:NVO) Wegovy pill is running three times ahead of rival Zepbound at the equivalent stage of launch, according to pharmacy data, a headline that implies dominant market positioning in oral GLP-1 therapeutics. But the data supporting that claim comes with substantial qualifications that tell a different story.

South Africa's High Court has ​granted Novo Nordisk an ‌interim interdict barring a local pharmacy group from manufacturing and ​selling compounded weight-loss medicines ​containing semaglutide, in a ruling ⁠that shows tightening scrutiny ​of unregistered drugs.

Deutsche Bank expects Novo Nordisk's (NYSE:NVO) pending ZEUS trial to miss, but sees limited upside even if the drug proves successful, given the company's looming patent cliff. The analyst has set a target of DKK290, just 3.6% above the last closing price of DKK280.10, and maintains a hold rating on the stock.

Keurig Dr Pepper, Novo Nordisk, Sonoco Products, Domino's Pizza, and Realty Income are top June dividend picks, all rated Buy or Strong Buy. KDP, NVO, SON, DPZ, and O are each trading 15–37% below estimated fair value, offering yields averaging 3.78% and projected annual returns of ~14%. I expect robust dividend growth and improving margins across these picks, with strong balance sheets and res...

The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, said it is important to continue studying the impact of GLP-1 medications on users' behavior and public safety as the medi...

A cyber ​extortion group claimed on Tuesday to have stolen more than a terabyte of data from pharmaceutical ‌giant Novo Nordisk and said it is exploring selling parts of the data after unsuccessfully demanding $25 million from the company.

Novo Nordisk has significantly regained the market's confidence as the Wegovy pill drives notable recovery and market share stabilization. NVO's international operations offset U.S. pricing pressures, with oral GLP-1 demand proving additive rather than cannibalistic to injectables. Despite a projected 7% sales decline in 2024, NVO maintains robust 41%+ operating margins and trades at historical...

Novo ​Nordisk plans ‌to seek Chinese ​regulatory ​approval for its ⁠weight-loss ​pill "very soon," ​CEO Mike Doustdar said ​Tuesday, ​in a move ‌to ⁠catch up with rival ​Eli ​Lilly ⁠in the ​world's ​second-largest ⁠pharmaceutical market.